Glaucoma remains the leading cause of irreversible blindness worldwide. There is a well-defined need for a long lasting and highly effective treatment to prevent global blindness. This makes the OptiShunt a very attractive investment opportunity for scientific research foundations.
The rapidly growing, billion dollar per annum glaucoma device market also means that the OptiShunt offers private equity investors and commercial partners the potential for excellent return on investment.
Contact Dr. McClunan to find out more about the OptiShunt project and its implications in ophthalmology.